{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-073439","form_type":"8-K","ticker":"LNTH","cik":"0001521036","company_name":"Lantheus Holdings, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.310015+00:00","generated_at":"2026-05-15T23:33:39.486565+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lantheus Q4 revenue $406.8M, adj EPS $1.67; narrows focus to PET radiodiagnostics","bullets":["Worldwide revenue $406.8M (+4% YoY); FY2025 revenue $1.54B; GAAP diluted EPS $0.82 Q4, $3.41 FY.","Adjusted diluted EPS $1.67 Q4 (+4.7% YoY), $6.08 FY; PYLARIFY sales $240.2M (-9.7%).","Company sharpens focus on innovative PET radiodiagnostics; pursuing alternatives for radiotherapeutic assets; completed SPECT divestiture to SHINE.","FY2026 guidance: revenue $1.4B-$1.45B, adjusted diluted EPS $5.00-$5.25.","Repurchased $100M of stock in Q4; cash and equivalents $359.1M after acquisitions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-073439","json":"https://secwatch.observer/filing/0001193125-26-073439.json","markdown":"https://secwatch.observer/filing/0001193125-26-073439.md","text":"https://secwatch.observer/filing/0001193125-26-073439.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1521036/000119312526073439/0001193125-26-073439-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1521036/000119312526073439/lnth-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:33:39.486565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}